Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Agrawal, A., Shrive, A.K., Greenhough, T.J., and Volanakis, J.E. (2001). Topology and structure of the C1q-binding site on C-reactive protein. J. Immunol., 166, 3998–4004.
Ahmed, N., Thorley, R., Xia, D., Samols, D., and Webster, R.O. (1996). Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am. J. Respir. Crit. Care Med., 153, 1141–1147.
Arend, W.P., Malyak, M., Guthridge, C.J., and Gabay, C. (1998). Interleukin-1 receptor antagonist: Role in biology. Annu. Rev. Immunol., 16, 27–55.
Ballou, S.P. and Kushner, I. (1992). C-reactive protein and the acute phase response. Adv. Intern. Med., 37, 313–336.
Becker, G.J., Waldburger, M., Hughes, G.R., and Pepys, M.B. (1980). Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann. Rheum. Dis., 39, 50–52.
Berger, P., McConnell, J.P., Nunn, M., Kornman, KS., Sorrell, J., Stephenson, K., and Duff, G.W. (2002). C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine, 17, 171–174.
Bharadwaj, D., Mold, C., Markham, E., and Du Clos, T.W. (2001). Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis. J. Immunol., 166, 6735–6741.
Bharadwaj, D., Stein, M.P., Volzer, M., Mold, C., and Du Clos, T.W. (1999). The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J. Exp. Med., 190, 585–590.
Bickerstaff, M.C., Botto, M., Hutchinson, W.L., Herbert, J., Tennent, G.A., Bybee, A., Mitchell, D.A., Cook, H.T., Butler, P.J., Walport, M.J., and Pepys, M.B. (1999). Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med., 5, 694–697.
Bodman-Smith, K.B., Gregory, R.E., Harrison, P.T., and Raynes, J.G. (2004). FcγRIIa expression with FcγRI results in C-reactive protein-and IgG-mediated phagocytosis. J. Leukoc. Biol., 75, 1029–1035.
Bodman-Smith, K.B., Melendez, A.J., Campbell, I., Harrison, P.T., Allen, J.M., and Raynes, J.G. (2002). C-reactive protein-mediated phagocytosis and phospholipase D signaling through the high-affinity receptor for immunoglobulin G (FcγRI). Immunology, 107, 252–260.
Brull, D.J., Serrano, N., Zito, F., Jones, L., Montgomery, H.E., Rumley, A., Sharma, P., Lowe, G.D., World, M.J., Humphries, S.E., and Hingorani, A.D. (2003). Human CRP gene polymorphism influences CRP levels: Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol., 23, 2063–2069.
Burlingame, R.W., Boey, M.L., Starkebaum, G., and Rubin, R.L. (1994). The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J. Clin. Invest., 94, 184–192.
Burlingame, R.W., Rubin, R.L., Balderas, R.S., and Theofilopoulos, A.N. (1993). Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J. Clin. Invest., 91, 1687–1696.
Burlingame, R.W., Volzer, M.A., Harris, J., and Du Clos, T.W. (1996). The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J. Immunol., 156, 4783–4788.
Carroll, M.C. (2000). A protective role for innate immunity in autoimmune disease. Clin. Immunol., 95, S30–S38.
Casciola-Rosen, L.A., Anhalt, G., and Rosen, A. (1994). Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med., 179, 1317–1330.
Chi, M., Tridandapani, S., Zhong, W., Coggeshall, K.M., and Mortensen, R.F. (2002). C-reactive protein induces signaling through FcγRIIa on HL-60 granulocytes. J. Immunol., 168, 1413–1418.
Clynes, R., Dumitru, C., and Ravetch, J.V. (1998). Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science, 279, 1052–1054.
Crowell, R.E., Du Clos, T.W., Montoya, G., Heaphy, E., and Mold, C. (1991). C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J. Immunol., 147, 3445–3451.
Du Clos, T.W. (1989). C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J. Immunol., 143, 2553–2559.
Du Clos, T.W. (1996). The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol. Biol. Rep., 23, 253–260.
Du Clos, T.W. (2000). Function of C-reactive protein. Ann. Med., 32, 274–278.
Du Clos, T.W. and Mold, C. (2003). C-reactive protein: Structure, synthesis and function. In S.Y. Wong and G. Arsequell (eds), Immunobiology of Carbohydrates. Kluwer Academic/Plenum Publishers, New York. pp. 39–55.
Du Clos, T.W., Mold, C., and Stump, R.F. (1990). Identification of a polypeptide sequence that mediates nuclear localization of the acute phase protein C-reactive protein. J. Immunol., 145, 3869–3875.
Du Clos, T.W., Zlock, L.T., Hicks, P.S., and Mold, C. (1994). Decreased autoantibody levels and enhanced survival of (NZB × NZW) F1 mice treated with C-reactive protein. Clin. Immunol. Immunopathol., 70, 22–27.
Familian, A., Zwart, B., Huisman, H.G., Rensink, I., Roem, D., Hordijk, P.L., Aarden, L.A., and Hack, C.E. (2001). Chromatin-independent binding of serum amyloid P component to apoptotic cells. J. Immunol., 167, 647–654.
Gabay, C., Roux-Lombard, P., de Moerloose, P., Dayer, J.M., Vischer, T., and Guerne, P.A. (1993). Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J. Rheumatol., 20, 815–821.
Gerber, J.S. and Mosser, D.M. (2001). Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors. J. Immunol., 166, 6861–6868.
Gershov, D., Kim, S., Brot, N., and Elkon, K.B. (2000). C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J. Exp. Med., 192, 1353–1363.
Gitlin, J.D., Gitlin, J.I., and Gitlin, D. (1977). Localization of C-reactive protein in synovium of patients with rheumatoid arthritis. Arthritis Rheum., 20, 1491–1499.
Han, K.H., Hong, K.H., Park, J.H., Ko, J., Kang, D.H., Choi, K.J., Hong, M.K., Park, S.W., and Park, S.J. (2004). C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation, 2566–2571.
Heuertz, R.M., Dongyuan, X., Samols, D., and Webster, R.O. (1994). Inhibition of C5a des Arginduced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am. J. Physiol., 266, L649–L654.
Heuertz, R.M., Tricomi, S.M., Ezekieli, U.R., and Webster, R.O. (1999). C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J. Biol. Chem., 275, 17968–17974.
Hicks, P.S., Saunero-Nava, L., Du Clos, T.W., and Mold, C. (1992). Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol., 149, 3689–3694.
Kushner, I. and Kaplan, M.H. (1961). Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits: Association with necrosis in inflammatory lesions. J. Exp. Med., 114, 961–973.
Li, Y.P., Mold, C., and Du Clos, T.W. (1994). Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J. Immunol., 152, 2995–3005.
Marnell, L.L., Mold, C., Volzer, M.A., Burlingame, R.W., and Du Clos, T.W. (1995). C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol., 155, 2185–2193.
Mold, C., Baca, R., and Du Clos, T.W. (2002a). Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcγ receptors. J. Autoimmunity, 19, 147–154.
Mold, C., Gresham, H.D., and Du Clos, T.W. (2001). Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. J. Immunol., 166, 1200–1205.
Mold, C., Nakayama, S., Holzer, T.J., Gewurz, H., and Du Clos, T.W. (1981). C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J. Exp. Med., 154, 1703–1708.
Mold, C., Rodic-Polic, B., and Du Clos, T.W. (2002b). Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fcγ receptors. J. Immunol., 168, 6375–6381.
Mold, C., Rodriguez, W., Rodic-Polic, B., and Du Clos, T.W. (2002c). C-reactive protein mediates protection from lipopolysaccharide through interactions with FcγR. J. Immunol., 169, 7019–7025.
Moore, K.W., Malefyt, R.D.W., Coffman, R.L., and O’Garra, A. (2001). Interleukin-10 and the Interleukin-10 receptor. Annu. Rev. Immunol., 19, 683–765.
Mortensen, R.F. and Duszkiewicz, J.A. (1977). Mediation of CRP-dependent phagocytosis through mouse macrophage Fc-receptors. J. Immunol., 119, 1611–1616.
Narkates, A.J. and Volanakis, J.E. (1982). C-reactive protein binding specificities: Artificial and natural phospholipid bilayers. Ann. N Y Acad. Sci., 389, 172–181.
Paul, A., Ko, K.W., Li, L., Yechoor, V., McCrory, M.A., Szalai, A.J., and Chan, L. (2004). C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109, 647–655.
Pepys, M.B., Baltz, M.L., Gomer, K., Davis, J.S., and Doenhoff, M. (1979). Serum amyloid P component is an acute phase reactant in mouse. Nature, 278, 259–261.
Pepys, M.B., Booth, S.E., Tennent, G.A., Butler, P.J.G., and Williams, D.G. (1994). Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin. Exp. Immunol., 97, 152–157.
Pepys, M.B., and Butler, P.J.G. (1987). Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun., 148, 308–313.
Ravetch, J.V. and Bolland, S. (2001). IgG Fc receptors. Annu. Rev. Immunol., 19, 275–290.
Ravetch, J.V. and Lanier, L.L. (2000). Immune inhibitory receptors. Science, 290, 84–89.
Ridker, P.M. (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107, 363–369.
Robey, F.A., Jones, K.D., Tanaka, T., and Liu, T.-Y. (1984). Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J. Biol. Chem., 259, 7311–7316.
Rodriguez, W., Mold, C., Kataranovski, M., Marnell, L., Hutt, J., and Du Clos, T.W. (2004). C-reactive protein reverses ongoing nephritis in autoimmune mice. Arthritis Rheum., 52, 642–650
Russell, A.I., Cunninghame Graham, D.S., Shepherd, C., Roberton, C.A., Whittaker, J., Meeks, J., Powell, R.J., Isenberg, D.A., Walport, M.J., and Vyse, T.J. (2004). Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet., 13, 137–147.
Soma, M., Tamaoki, T., Kawano, H., Ito, S., Sakamoto, M., Okada, Y., Ozaki, Y., Kanba, S., Hamada, Y., Ishihara, T., and Maeda, S. (2001). Mice lacking serum amyloid P component do not necessarily develop severe autoimmune disease. Biochem. Biophys. Res. Commun., 286, 200–205.
Stein, M.P., Mold, C., and Du Clos, T.W. (2000). C-reactive protein binding to murine leukocytes requires Fcγ receptors. J. Immunol., 164, 1514–1520.
Sutterwala, F.S., Noel, G.J., Salgame, P., and Mosser, D.M. (1998). Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. J. Exp. Med., 188, 217–222.
Szalai, A.J., McCrory, M.A., Cooper, G.S., Wu, J., and Kimberly, R.P. (2002b). Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun., 3, 14–19.
Szalai, A.J., Nataf, S., Hu, X.-Z., and Barnum, S.R. (2002a). Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol., 168, 5792–5797.
Szalai, A.J., Weaver, C.T., McCrory, M.A., van Ginkel, F.W., Reiman, R.M., Kearney, J.F., Marion, T.N., and Volanakis, J.E. (2003). Delayed lupus onset in (NZB × NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum., 48, 1602–1611.
Tarzi, R.M., Davies, K.A., Claassens, J.W., Verbeek, J.S., Walport, M.J., and Cook, H.T. (2003). Both Fcγ receptor I and Fcγ receptor III mediate disease in accelerated nephrotoxic nephritis. Am. J. Pathol., 162, 1677–1683.
Tarzi, R.M., Davies, K.A., Robson, M.G., Fossati-Jimack, L., Saito, T., Walport, M.J., and Cook, H.T. (2002). Nephrotoxic nephritis is mediated by Fcγ receptors on circulating leukocytes and not intrinsic renal cells. Kidney Int., 62, 2087–2096.
Tebo, J.M. and Mortensen, R.F. (1990). Characterization and isolation of a C-reactive protein receptor from the human monocytic cell line U-937. J. Immunol., 144, 231–238.
ter Borg, E.J., Horst, G., Limburg, P.C., van Rijswijk, M.H., and Kallenberg, C.G. (1990). C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study. J. Rheumatol., 17, 1642–1648.
Theofilopoulos, A.N. and Dixon, F.J. (1985). Murine models of systemic lupus erythematosus. Adv. Immunol., 37, 269–391.
Thompson, D., Pepys, M.B., and Wood, S.P. (1999). The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 7, 169–177.
Tilg, H., Vannier, E., Vachino, G., Dinarello, C.A., and Mier, J.W. (1993). Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of Interleukin 1 (IL-1) receptor antagonist over IL-1b synthesis by human peripheral blood mononuclear cells. J. Exp. Med., 178, 1629–1636.
Tillett, W.S. and Francis, T., Jr. (1930). Serological reactions in pneumonia with a non-protein fraction of pneumococcus. J. Exp. Med., 52, 561–571.
Vickers, M.A., Green, F.R., Terry, C., Mayosi, B.M., Julier, C., Lathrop, M., Ratcliffe, P.J., Watkins, H.C., and Keavney, B. (2002). Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc. Res., 53, 1029–1034.
Volanakis, J.E. (2001). Human C-reactive protein: Expression, structure, and function. Mol. Immunol., 38, 189–197.
Volanakis, J.E. and Kaplan, M.H. (1971). Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med., 136, 612–614.
Walport, M.J. (2000). Lupus, DNase and defective disposal of cellular debris. Nat. Genet., 25, 135–136.
Whitehead, A.S., Zahedi, K., Rits, M., Mortensen, R.F., and Lelias, J.M. (1990). Mouse C-reactive protein generation of cDNA clones, structural analysis, and induction of mRNA during inflammation. Biochem. J., 266, 283–290.
Xia, D. and Samols, D. (1997). Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc. Natl. Acad. Sci. USA., 94, 2575–2580.
Zahedi, K., Tebo, J.M., Siripont, J., Klimo, G.F., and Mortensen, R.F. (1989). Binding of human C-reactive protein to mouse macrophages is mediated by distinct receptors. J. Immunol., 142, 2384–2392.
Zee, R.Y. and Ridker, P.M. (2002). Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis, 162, 217–219.
Zein, N., Ganuza, C., and Kushner, I. (1979). Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum., 22, 7–12.
Zwaka, T.P., Hombach, V., and Torzewski, J. (2001). C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation, 103, 1194–1197.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Du Clos, T.W., Mold, C. (2005). C-Reactive Protein as a Regulator of Autoimmune Disease. In: Zouali, M. (eds) Molecular Autoimmunity. Springer, Boston, MA. https://doi.org/10.1007/0-387-24534-0_3
Download citation
DOI: https://doi.org/10.1007/0-387-24534-0_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24533-1
Online ISBN: 978-0-387-24534-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)